natgillin/translations-raw huggingface dataset:
Den maksimale dosis Xultophy var 50 dosistrin, mens der ikke var nogen maksimumdosis i armen med insulin degludec.
The maximum dose of Xultophy was 50 dose steps, while there was no maximum dose in the insulin degludec arm.
Den maksimale dosis, der er blevet anvendt til behandling af Cushings syndrom, er 1.600 mg/dag.
The maximal dose that was used for treatment of Cushing’s syndrome is 1600 mg/day.
Den maksimale koncentration af liraglutid blev estimeret til 9,4 nmol/l for én subkutan dosis liraglutid på 0,6 mg.
Estimated maximum liraglutide concentration was 9.4 nmol/l for a subcutaneous single dose of liraglutide 0.6 mg.
Den maksimale målte plasmakoncentration af retapamulin var 10,7 ng/ml hos voksne og 18,5 ng/ml hos børn (i alderen 2-17 år).
The maximum measured plasma concentration of retapamulin was 10.7 ng/ml in adults and 18.5 ng/ml in paediatric patients (aged 2-17 years).
Den maksimale mætnings dosis på Dag 1 måikke overstige 70 mg uanset den beregnede dosis.
The maximum loading dose on Day 1 should not exceed 70 mg regardless of the patient's calculated dose.
Den maksimale Mætningsdosis på Dag 1 må ikke overstige 70 mg uansetden beregnede dosis.
The maximum loading dose on Day 1 should not exceed 70 mg regardless of the patient's calculated dose.
Den maksimale mætningsdosis på Dag 1 måikke overstige 70 mg uanset den beregnede dosis.
The maximum loading dose on Day 1 should not exceed 70 mg regardless of the patient's calculated dose.
Den maksimale plasmakoncentration (Cmax) var ca.
The maximum concentration (Cmax) in plasma was approximately
Den maksimale plasmakoncentration opnås inden for 3–5 timer.
The maximum plasma concentrations are attained within 3–5 hours.
Den maksimale Rapamune-dosis, som gives på en hvilken som helst dag, bør ikke over- stige 40 mg.
The maximum Rapamune dose administered on any day should not exceed 40 mg.
Den maksimale respons blev generelt opnået inden for 1 til 2 uger efter dosering med 140 mg hver anden uge og 420 mg én gang om måneden.
Maximal response was generally achieved within 1 to 2 weeks after dosing with 140 mg every 2 weeks and 420 mg once monthly.
Den maksimale serum- koncentration (Cmax) og arealet under serum-koncentration/tidskurven (AUC) forekom forhøjet fra den enkelte til den dobbelte dosis, selvom denne forhøjelse ikke var dosis-proportional.
The maximum serum concentration (Cmax) and area under the serum concentration-time curve (AUC) appeared to increase from the single to double dose, although the increase was not dose-proportional.
Den maksimale tid, der må forløbe fra optøning til infusion, er 2 timer ved stuetemperatur (15 °C-30 °C).
Maximum time elapsed from thawing and infusion is 2 hours at room temperature (15 °C – 30 °C).
Den maksimale tolererede dosis clofarabin identificeret i det ovenfor beskrevne fase I-studie, 52 mg/m2/dag, blev administreret som intravenøs infusion 5 dage i træk hver 2. – 6. uge.
The maximum tolerated dose identified in the phase I study described above of 52 mg/m2/day clofarabine was administered by intravenous infusion for 5 consecutive days every 2 to 6 weeks.
Den maksimale totale dosis Glybera til administration er 1 × 1012 gc/kg legemsvægt.
The maximum total dose of Glybera for administration is 1 x 1012 gc/kg body weight.
Den maksimale virkning opnås mellem 1,5 og 4 timer efter injektion, og virkningsvarigheden er 12 - 16 timer.
4 hours after injection and the duration of action is 12 to 16 hours.
Den maksimale volumen ved den højeste dosis er 6 ml.
The maximum volume of the highest dose is 6ml.
Den maksimale, ikke-letale, orale dosis indinavir var mindst 5000 mg/kg hos rotter og mus, den højeste dosis undersøgt i akutte toksicitetsundersøgelser.
The maximum non–lethal oral dose of indinavir was at least 5,000 mg/kg in rats and mice, the highest dose tested in acute toxicity studies.
Den maksimale, uskadelige dosis epoetin delta som kan gives, enten som enkel dosis eller multi dosis, er ikke fastsat.
The maximum dose of epoetin delta that can be safely administered in single or multiple doses has not been determined.
Den maksimalt anbefalede daglige dosis er 8 mg/2 000 mg.
The maximum recommended daily dose is 8 mg/2,000 mg.
Den maksimalt tolererede dosis af Perjeta er ikke fastlagt.
The maximum tolerated dose of Perjeta has not been determined.
Den maksimalt tolererede dosis i fase I-studierne var 4-6 mg/m2 med meget varierende bivirkninger.
The maximum tolerated dose in phase I studies was 4-6 mg/m2 with a high variability of adverse reactions.
Den maksimalt tolererede ipilimumab–dosis er ikke blevet fastlagt.
The maximum tolerated dose of ipilimumab has not been determined.
Den maksimalt tolererede pazopanibdosis hos patienter med moderat nedsat leverfunktion (defineret som forhøjet bilirubin > 1,5-3 gange den øvre normalgrænse uanset ALAT-niveau) var 200 mg én gang daglig.
The maximally tolerated pazopanib dose (MTD) in patients with moderate hepatic impairment (defined as an elevation of bilirubin > 1.5 x to 3 x ULN regardless of the ALT values) was 200 mg once daily.
Den maternelle systemiske eksponering ved niveauet uden observerbare effekter (NOEL) for neonatal toksicitet var cirka 3 gange den humane eksponering.
The maternal systemic exposure at the no observed effect level (NOEL) for neonatal toxicity was about 3 times human exposure.
Den mavesyrehæmmende virkning fra esomeprazol og andre PPI’er kan muligvis mindske eller øge absorptionen af lægemidler med gastrisk pH-afhængig absorption.
Gastric acid suppression during treatment with esomeprazole and other PPIs might decrease or increase the absorption of medicinal products with a gastric pH dependent absorption.
Den medfølgende solvens bruges til at fortynde koncentratet til den fortynding, der muliggør en optimering af injektionsvolumenet for fisk med stor variation i legemsvægt.
The supplied solvent is used to dilute the concentrate to the correct dilution to allow for optimisation of the preferred injection volumes for fish of widely varying body weights.
Den medfølgende sprøjtebør ikke anvendes til andre lægemidler.
The supplied oral dosing pipette should not be used for any other medicinal products.
Den medfølgende Valtropin-solvens indeholder metacresol.
The accompanying solvent of Valtropin contains metacresol.
Den mediane (kvartil 1, kvartil 3) tid, indtil korrektion af hæmoglobin var opnået ( ≥ 10,0 g/dl og ≥ 1,0 g/dl stigning i forhold til baseline), var 5 uger for både dosering én gang hver anden uge (3, 7 uger) og én gang månedligt (3, 9 uger).
The median (quartile1, quartile 3) time to achieve haemoglobin correction (≥ 10.0 g/dl and ≥ 1.0 g/dl increase from baseline) was 5 weeks for both once every two week (3, 7 weeks) and once monthly dosing (3, 9 weeks).
Den mediane (min.-maks.) nyre-clearance af adefovir hos forsøgspersoner med normal nyrefunktion (Clcr > 80 ml/min) er 211 ml/min (172-316 ml/min), dvs. ca. dobbelt så stor som den beregnede kreatininclearance (Cockroft-Gault metoden).
The median (min-max) renal clearance of adefovir in subjects with normal renal function (Clcr > 80 ml/min) is 211 ml/min (172-316 ml/min), approximately twice calculated creatinine clearance (Cockroft-Gault method).
Den mediane (Q1, Q3) ændring fra baseline i forholdet mellem total kolesterol og HDL-kolesterol ved uge 96 var 0,1 (-0,3; 0,7) i Genvoya-gruppen og 0,0 (-0,4; 0,5) i E/C/F/TDF-gruppen (p < 0,001 for forskellen mellem behandlingsgrupperne).
The median (Q1, Q3) change from baseline in total cholesterol to HDL-cholesterol ratio at Week 96 was 0.1 (-0.3, 0.7) in the Genvoya group and 0.0 (-0.4, 0.5) in the E/C/F/TDF group (p < 0.001 for the difference between treatment groups).
Den mediane (Q1, Q3) ændring fra baseline i forholdet mellem total kolesterol og HDL-kolesterol ved uge 96 var 0,1 (-0,3; 0,7) i gruppen med E/C/F/TAF og 0,0 (-0,4; 0,5) i gruppen med E/C/F/TDF (p < 0,001 for forskellen mellem behandlingsgrupperne).
The median (Q1, Q3) change from baseline in total cholesterol to HDL-cholesterol ratio at Week 96 was 0.1 (-0.3, 0.7) in the E/C/F/TAF group and 0.0 (-0.4, 0.5) in the E/C/F/TDF group (p < 0.001 for the difference between treatment groups).
Den mediane ABR ved profylaktisk behandling med RIXUBIS var 2,0 for alle blødninger, 0,0 for spontane blødninger og 0,0 for ledblødninger.
The median ABR on prophylaxis with RIXUBIS for all bleeds was 2.0, for spontaneous bleeds 0.0, and for joint bleeds 0.0. 24 subjects (42.9%) experienced zero bleeds.
Den mediane alder var 47 år (20-74) i siltuximab-armen og 48 år (27-78) i placeboarmen.
Median age was 47 years (range 20-74) in the siltuximab arm and 48 years (range 27-78) in the placebo arm.
Den mediane behandlingsvarighed for patienterne var 3,9 måneder i Abraxane/gemcitabin-armen, og 2,8 måneder i gemcitabin-armen.
Patients received a median treatment duration of 3.9 months in the Abraxane/gemcitabine arm and 2.8 months in the gemcitabine arm.
Den mediane behandlingsvarighed i behandlingsgruppen med 100 mg 1 gang dagligt var 37 måneder (1-91 måneder).
The median duration of therapy in the 100 mg once daily group was 37 months (range 1-91 months).
Den mediane behandlingsvarighed i publiceret litteratur varierede mellem 4 uger og mere end 20 måneder.
The median duration of therapy in the published literature ranged between 4weeks and more than 20months.
Den mediane behandlingsvarighed med DARZALEX var 3,3 måneder, og den længste behandlingsvarighed var 20 måneder.
The median duration of DARZALEX treatment was 3.3 months, with the longest duration of treatment being 20 months.
Den mediane behandlingsvarighed med dasatinib var 14 måneder og 31% af patienterne er til dato behandlet i > 24 måneder.
Median duration of treatment on dasatinib was 14 months with 31% of patients treated for > 24 months to date.
Den mediane behandlingsvarighed med dasatinib var 24 måneder med 51% af patienterne behandlet i > 24 måneder til dato.
Median duration of treatment on dasatinib was 24 months with 51% of patients treated for > 24 months to date.
Den mediane behandlingsvarighed med studielægemidlet var 118 uger; 25 % af patienterne seponerede inden uge 48.
The median time on study therapy was 118 weeks; 25% of patients discontinued before Week 48.
Den mediane behandlingsvarighed var 101 uger.
The median duration of treatment was 101 weeks.
Den mediane behandlingsvarighed var 24,0 uger, og det mediane antal behandlingscyklusser var 6,0, hvilket var konsistent for alle behandlingsgrupper.
Due to this early crossover, the median duration of follow-up for surviving patients is 8.3 months.
Den mediane behandlingsvarighed var 44,0 uger (min: 0,1; max: 254,9) for lenalidomid/dexamethason og 23,1 uger (min: 0,3; max: 238,1) for placebo/dexamethason.
The median duration of treatment was 44.0 weeks (min: 0.1, max: 254.9) for lenalidomide/dexamethasone and 23.1 weeks (min: 0.3, max: 238.1) for placebo/dexamethasone.
Den mediane behandlingsvarighed var 7,6 måneder (0,3-20,5) for patienter, der fik CABOMETYX, og 4,4 måneder (0,21-18,9) for patienter, der fik everolimus.
The median duration of treatment was 7.6 months (range 0.3 – 20.5) for patients receiving CABOMETYX and 4.4 months (range 0.21 – 18.9) for patients receiving everolimus.
Den mediane DOR for alle patienter var 12,5 måneder (12,5 måneder for patienter med SLL og ikke nået for patienter med FL, LPL/WM og MZL).
The median DOR for all subjects was 12.5 months (12.5 months for SLL subjects, and not reached for FL, LPL/WM and MZL subjects).
Den mediane eksponeringvarighed var 67,8 måneder (interval 4,7 til 83,2).
The median duration of exposure was 67.8 months (range 4.7 to 83.2).
Den mediane follow-up-tid på tidspunktet for de primære analyser i intent-to-treat-populationen var 1,5 år; data fra analyser efter yderligere et års follow-up fremgår også af tabel 7.
The median follow up at the time of the primary analyses in the intent-to-treat population was 1.5 years; data from analyses following an additional 1 year of follow up are also included in Table 7.
Den mediane forbedring fra baseline til slutning af del I af studie G2301 var 0,88 (79 %).
The median improvement from baseline to end of part I of study G2301 was 0.88 (79%).
Den mediane gennemsnitsdosis pr. injektion til behandling af en blødningsepisode var 63,51 (interkvartilt interval 48,92-99,44) IU/kg.
The median average dose per injection to treat a bleeding episode was 63.51 (interquartile range, 48.92-99.44) IU/kg.
Den mediane infusionsvarighed for første, anden og efterfølgende infusioner var henholdsvis 7,0, 4,6 og 3,4 timer.
Median durations of infusion for the first, second and subsequent infusions were 7.0, 4.6 and 3.4 hours respectively.
Den mediane kumulative dosis indtil behandlingsophør var mere end 1.000 mg/m2 , og mediantiden indtil reversibilitet af væskeretention var 16,4 uger (interval 0 til 42 uger).
The median cumulative dose to treatment discontinuation was more than 1,000 mg/m2 and the median time to fluid retention reversibility was 16.4 weeks (range 0 to 42 weeks).
Den mediane kumulative dosis til behandlingsophør var mere end 1.000 mg/m² og median-tiden til reversibilitet af væskeretention var 16,4 uger (varighed 0 til 42 uger).
The median cumulative dose to treatment discontinuation was more than 1,000 mg/m² and the median time to fluid retention reversibility was 16.4 weeks (range 0 to 42 weeks).
Den mediane kumulative dosis til behandlingsophør var mere end 1000 mg/m2 og mediantiden til reversibilitet af væskeretention var 16,4 uger (interval 0 til 42 uger).
The median cumulative dose to treatment discontinuation was more than 1,000 mg/m2 and the median time to fluid retention reversibility was 16.4 weeks (range 0 to 42 weeks).
Den mediane OS for patienter med enhver grad af neutropeni var længere i ramucirumab- armen (16,1 måneder) end i placebo-armen (12,6 måneder).
The median OS in patients with any grade neutropenia was greater in the ramucirumab arm (16.1 months) than in the placebo arm (12.6 months).
Den mediane OS for patienter med NSCLC bortset fra cancer hovedsageligt bestående af pladeepitelceller (N = 481) var 15,5 måneder for pemetrexed-armen og 10,3 måneder for placeboarmen (hazard ratio = 0,70, 95 % CI = 0,56 – 0,88, p = 0,002).
The median OS for patients with NSCLC other than predominantly squamous cell histology (N = 481) was 15.5 months for the pemetrexed arm and 10.3 months for the placebo arm, hazard ratio = 0.70 (95% CI = 0.56-0.88, p = 0.002).
Den mediane OS, herunder langvarig opfølgning for alle 125 patienter, var 20,3 måneder.
The median OS, including long-term follow-up for all 125 subjects, was 20.3 months.
Den mediane overlevelse var 30,3 uger (95 % CI: 27,6 og 33,4).
The median survival was 30.3 weeks (95 % CI: 27.6, 33.4).
Den mediane overlevelse var 392 dage (capecitabin) vs.
Median survival was 392 days (capecitabine) vs.
Den mediane overlevelse var 442 dage (docetaxel + capecitabin) vs.
Median survival was 442 days (capecitabine + docetaxel) vs.
Den mediane overlevelse var 442 dage (docetaxel + capecitabin) vs.
Median survival was 442 days (docetaxel + capecitabine) vs.
Den mediane PFS for patienter randomiseret til placebo var 19,3 måneder.
The median PFS for patients randomized to placebo was 19.3 months.
Den mediane PFS for patienter randomiseret til vandetanib er ikke blevet nået; dog er den mediane PFS baseret på statistisk modellering af data observeret op til den 43. percentil at være prædikteret til 30,5 måneder med et 95% konfidens-interval på 25,5 til 36,5 måneder.
The median PFS for patients randomized to vandetanib has not been reached; however, based on statistical modelling of data observed up to the 43rd percentile, the median PFS is predicted to be months with 95% confidence interval 25.5 to 36.5 months.
Den mediane PFS var 11,4 måneder for sunitinib og 5,5 måneder for placebo [hazard ratio: 0,418 (95% CI: 0,263- 0,662), p = 0,0001]; lignende resultater blev set, når responsvurdering baseret på RECIST, sammenholdt med investigator-tumor-måling blev brugt til at bestemme sygdomsprogression, som vist i tabel 4.
The median PFS was 11.4 months for the sunitinib arm compared to 5.5 months for the placebo arm [hazard ratio: 0.418 (95% CI: 0.263, 0.662), p-value = 0.0001]; similar results were observed when derived tumour response assessments based upon application of RECIST to investigator tumour measurements were used to determine disease progression, as shown in Table 4.
Den mediane progressionsfri overlevelse og samlede overlevelse var kortere for XELIRI versus FOLFIRI (progressionsfri overlevelse 5,9 måneder versus 9,6 måneder og samlet overlevelse 14,8 versus 19,9 måneder).
Median PFS and overall survival (OS) times were shorter for XELIRI versus FOLFIRI (PFS
Den mediane relative dosisintensitet af paclitaxel var 87,7 % for Cyramza plus paclitaxel- gruppen og 93,2 % for placebo plus paclitaxel-gruppen.
The median relative dose intensity of paclitaxel was 87.7% for the Cyramza plus paclitaxel arm and 93.2% for the placebo plus paclitaxel arm.
Den mediane responsvarighed var 37,7 måneder i R-CVP-gruppen og 13,5 måneder i CVP-gruppen (p < 0,0001), log rank test).
The median duration of response was 37.7 months in the R-CVP group and was 13.5 months in the CVP group (p < 0.0001, log-rank test).
Den mediane responsvarighed var 37,7 måneder i R-CVP-gruppen, og den var 13,5 måneder i CVP- gruppen (p < 0,0001), log rank test).
The median duration of response was 37.7 months in the R-CVP group and was 13.5 months in the CVP group (p < 0.0001, log-rank test).
Den mediane rPFS blev ikke nået (95 % KI: 13,8; ikke nået) i enzalutamidgruppen og var 3,9 måneder (95 % KI: 3,7; 5,4) i placebogruppen (figur 3).
The median rPFS was not reached (95% CI: 13.8, not reached) in the enzalutamide-treated group and was 3.9 months (95% CI: 3.7, 5.4) in the placebo-treated group (Figure 3).
Den mediane samlede dosis til behandling af en blødningsepisode var 31,32 IU/kg (23,53; 52,53) i armen med individualiseret profylakse og i armen med ugentlig profylakse, og 27,35 IU/kg (22,59; 32,71) i armen med behandling ved behov.
The median overall dose to treat a bleeding episode was 31.32 IU/kg (23.53, 52.53) in the individualised prophylaxis arm and in the weekly prophylaxis arm and 27.35 IU/kg (22.59, 32.71) in the on demand treatment arm.
Den mediane samlede overlevelse i den forlængede opfølgningsanalyse af de poolede resultater er 164,3 uger (95 %- konfidensinterval: 145,1; 192,6) hos patienter behandlet med lenalidomid/dexamethason versus 136,4 uger (95 %-konfidensinterval: 113,1; 161,7) hos patienter behandlet med placebo/dexamethason.
The median overall survival in the extended follow-up analysis of the pooled studies is 164.3 weeks (95% CI: 145.1, 192.6) in patients treated with lenalidomide/dexamethasone versus 136.4 weeks (95% CI: 113.1, 161.7) in patients treated with placebo/dexamethasone.
Den mediane samlede overlevelse var 10,0 måneder for de cisplatinbaserede regimer og 10,4 måneder for de oxaliplatin- baserede regimer.
The median overall survival was 10.0 months in cisplatin-based regimens and 10.4 months in oxaliplatin-based regimens.
Den mediane samlede overlevelse var 10,0 måneder for de cisplatinbaserede regimer og 10,4 måneder for de oxaliplatin-baserede regimer.
The median overall survival was 10.0 months in cisplatin-based regimens and 10.4 months in oxaliplatin- based regimens.
Den mediane samlede overlevelse var 6,9 måneder (vinflunin + BSC) vs.
The median overall survival was 6.9 months (vinflunine + BSC) vs.
Den mediane samlede overlevelse var 703 dage (95 % konfidensinterval: 671, 745) hos patienter, som blev behandlet med regimer, der indeholdt capecitabin og 683 dage (95 % konfidensinterval: 646, 715) hos patienter, som blev behandlet med regimer, der indeholdt 5-FU.
Median overall survival time was 703 days (95% CI: 671; 745) in patients treated with capecitabine -containing regimens and 683 days (95% CI: 646; 715) in patients treated with 5-FU-containing regimens.
Den mediane samlede overlevelse var endnu ikke nået i nogen af armene.
The median overall survival (OS) was not yet reached for either arm.
Den mediane sekundære PFS (målt efter investigatorens bedømmelse) var hhv.
The median secondary PFS (as measured by the investigator’s assessment) were
Den mediane stigning fra baseline for disse parametre var større hos patienter, der fik emtricitabin+ tenofoviralafenamid sammenlignet med patienter, der fik emtricitabin+tenofovirdisoproxilfumarat, begge givet med elvitegravir+cobicistat som fastdosis kombinationstablet (p < 0,001 for forskellen mellem behandlingsgrupperne angående fastende total kolesterol, direkte LDL- og HDL-kolesterol samt triglycerider).
The median increase from baseline for these parameters was greater in patients receiving emtricitabine+tenofovir alafenamide compared with patients receiving emtricitabine+tenofovir disoproxil fumarate, both given with elvitegravir+cobicistat as a fixed-dose combination tablet (p < 0.001 for the difference between treatment groups for fasting total cholesterol, direct LDL- and HDL-cholesterol, and triglycerides).
Den mediane stigning fra baseline for disse parametre var større i Genvoya-gruppen sammenlignet med E/C/F/TDF- gruppen ved uge 96 (p < 0,001 for forskellen mellem behandlingsgrupperne for fastende total kolesterol, direkte LDL- og HDL-kolesterol samt triglycerider).
The median increase from baseline for those parameters was greater in the Genvoya group compared with the E/C/F/TDF group at Week 96 (p < 0.001 for the difference between treatment groups for fasting total cholesterol, direct LDL- and HDL-cholesterol, and triglycerides).
Den mediane stigning fra baseline for disse parametre var større i gruppen med E/C/F/TAF sammenlignet med gruppen med elvitegravir 150 mg/cobicistat 150 mg/emtricitabin 200 mg/tenofovirdisoproxil (som fumarat) 245 mg (E/C/F/TDF) ved uge 96 (p < 0,001 for forskellen mellem behandlingsgrupperne for fastende total kolesterol, direkte LDL- og HDL-kolesterol samt triglycerider).
The median increase from baseline for those parameters was greater in the E/C/F/TAF group compared with the elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil (as fumarate) 245 mg (E/C/F/TDF) group at Week 96 (p < 0.001 for the difference between treatment groups for fasting total cholesterol, direct LDL- and HDL-cholesterol, and triglycerides).
Den mediane stigning i CD4+ tal ved uge 48 fra baseline var 128 celler/mm3, og den mediane stigning i CD4+ procent var 5 %.
The median increase from baseline in CD4+ count at 48 weeks of therapy was 128 cells/mm3 and the median increase in CD4+ percentage was 5%.
Den mediane stigning i CD4+ tal ved uge 48 fra baseline var 215 celler/mm3, og den mediane stigning i CD4+ procent var 6 %.
The median increase from baseline in CD4+ count at 48 weeks was 215 cells/mm3 and the median increase in CD4+ percentage was 6%.
Den mediane stigning i CD4+ tal ved uge 48 fra baseline var 238 celler/mm3, og den mediane stigning i CD4+ procent var 13 %.
The median increase from baseline in CD4+ count at 48 weeks of therapy was 238 cells/mm3 and the median increase in CD4+ percentage was 13%.
Den mediane stigning i hæmoglobin (Hgb) fra baseline i armen med 10 mg var 6,4 g/dl (4,0 mmol/l).
The median increase in haemoglobin (Hgb) from baseline in the 10 mg arm was 6.4 g/dL.
Den mediane stigning i hæmoglobin (Hgb) var 5,6 g/dl (3,5 mmol/l).
The median increase in haemoglobin (Hgb) was 5.6 g/dL.
Den mediane tid fra diagnose til start af behandling var 82 måneder.
The median time from diagnosis to start of treatment was 82 months.
Den mediane tid fra start af pemetrexed og cisplatin induktionsbehandling til start af vedligeholdelsesbehandling var 2,96 måneder i både pemetrexed- og placeboarmen.
The median time from the start of pemetrexed plus cisplatin induction therapy to the start of maintenance treatment was 2.96 months on both the pemetrexed arm and the placebo arm.
Den mediane tid indtil progression var 186 dage (capecitabin + docetaxel) vs.
The median time to progression was 186 days (capecitabine + docetaxel) vs.
Den mediane tid indtil progression var 186 dage (docetaxel + capecitabin) vs.
The median time to progression was 186 days (docetaxel + capecitabine) vs.
Den mediane tid indtil progression var 186 dage (docetaxel+ capecitabin) vs.
The median time to progression was 186 days (docetaxel + capecitabine) vs.